Perrigo Co PLC
- Last sale
- Nov 12, 2026 · -2.24%
- Market cap
- $2.25B
- 138.8M shares
- Filings
- 1,039
Q3 2026−2.8% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derived−40.7% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−4.9% FY25 yoy
- $2.25B
- —
- 0.5×
- 0.9×
- 7.49%
- 7.13%
Twelve months to Sep 26, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $4,253,100,000 | reported | |
| FY 2024 | 2024-12-31 | $4,373,400,000 | reported | |
| FY 2023 | 2023-12-31 | $4,655,600,000 | reported | |
| FY 2022 | 2022-12-31 | $4,451,600,000 | reported | |
| FY 2021 | 2021-12-31 | $4,138,700,000 | reported | |
| FY 2020 | 2020-12-31 | $4,088,200,000 revised | reported | |
| FY 2019 | 2019-12-31 | $3,869,900,000 revised | reported | |
| FY 2018 | 2018-12-31 | $4,731,700,000 | reported | |
| FY 2017 | 2017-12-31 | $4,946,200,000 | reported | |
| FY 2016 | 2016-12-31 | $5,280,600,000 | reported | |
| FY 2015 | 2015-06-27 | $4,227,100,000 revised | reported | |
| FY 2014 | 2014-06-28 | $3,914,100,000 revised | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $159.30M | — | $159.30M | $1.16 | 137.65M sh | +0.9% | 109.8% |
| FY2024 | $152.50M | — | $152.50M | $1.10 | 136.46M sh | +0.7% | 62.3% |
| FY2023 | $149.70M | — | $149.70M | $1.09 | 135.52M sh | +0.6% | 49.3% |
| FY2022 | $142.40M | $0.00 | $142.40M | $1.04 | 134.65M sh | +0.6% | 67.5% |
| FY2021 | $129.60M | $0.00 | $129.60M | $0.96 | 133.78M sh | +0.5% | 3085.7% |
Segments
LineFY2025ShareChange
CSCA$2.59B61%−4.0%
CSCI$1.67B39%−0.7%
RX Pharmaceuticals———
Total$4.25B
Pharmaceutical preparations
Perrigo Co PLC is the 20th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
ONCBeOne Medicines Ltd.$5.3B40.2%5.4%$617.8BELANElanco Animal Health Inc$4.7B6.2%4.9%$13.3BJAZZJazz Pharmaceuticals plc$4.3B4.9%8.3%$15.4B
PRGOPerrigo Co PLC (this company)$4.3B2.8%33.5%$2.2B
GMABGenmab A/S$3.7B19.2%25.9%—ALNYAlnylam Pharmaceuticals, Inc.$3.7B65.2%8.4%$21.0BBMRNBioMarin Pharmaceutical Inc$3.2B12.9%10.8%$11.0BUTHRUnited Therapeutics Corp$3.2B10.6%41.9%$25.3BAMRXAmneal Pharmaceuticals, Inc.$3.0B8.0%2.4%$7.5BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Perrigo Co PLC · CIK 1585364 · Engraved from SEC EDGAR